{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T02:02:19Z","timestamp":1784599339798,"version":"3.55.0"},"reference-count":25,"publisher":"ARAN Ediciones","issue":"3","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hipertensi\u00f3n y Riesgo Vascular"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.hipert.2020.02.005","type":"journal-article","created":{"date-parts":[[2020,3,8]],"date-time":"2020-03-08T13:11:38Z","timestamp":1583673098000},"page":"101-107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The effect of renin\u2013angiotensin\u2013aldosterone system blockers on the progression of chronic kidney disease in hypertensive elderly patients without proteinuria: PROERCAN study. Rationale and design"],"prefix":"10.20960","volume":"37","author":[{"given":"A.M.","family":"Garc\u00eda-Prieto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00da.","family":"Verdalles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.P.","family":"de Jos\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Verde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Arroyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Aragoncillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Linares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Goicoechea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8588","reference":[{"key":"10.1016\/j.hipert.2020.02.005_bib0130","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0140-6736(13)60687-X","article-title":"Chronic kidney disease: global dimension and perspectives","volume":"382","author":"Jha","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.hipert.2020.02.005_bib0135","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1471-2458-8-117","article-title":"Prevalence of chronic kidney disease in population-based studies: systematic review","volume":"8","author":"Zhang","year":"2008","journal-title":"BMC Public Health"},{"key":"10.1016\/j.hipert.2020.02.005_bib0140","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1681\/ASN.2005090986","article-title":"Mortality risk stratification in chronic kidney disease: one size for all ages?","volume":"17","author":"O\u2019Hare","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.hipert.2020.02.005_bib0145","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/kisup.2012.50","article-title":"KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease: summary of recommendation statements","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.hipert.2020.02.005_bib0150","doi-asserted-by":"crossref","first-page":"244","DOI":"10.7326\/0003-4819-139-4-200308190-00006","article-title":"AIPRD Study Group Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis","volume":"139","author":"Jafar","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hipert.2020.02.005_bib0155","doi-asserted-by":"crossref","first-page":"717","DOI":"10.7326\/0003-4819-150-10-200905190-00010","article-title":"Current guidelines for using angiotensin-converting enzyme inhibitors and angiotensin II-receptor antagonists in chronic kidney disease: is the evidence base relevant to older adults?","volume":"19","author":"O\u2019Hare","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hipert.2020.02.005_bib0160","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"ESC Scientific Document Group 2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hipert.2020.02.005_bib0165","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.2215\/CJN.01580210","article-title":"Effect of allopurinol in chronic kidney disease progression and cardiovascular risk","volume":"5","author":"Goicoechea","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.hipert.2020.02.005_bib0170","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa0801369","article-title":"HYVET Stdy Group Treatment of Hypertension in patients 80 years of age or older","volume":"358","author":"Beckett","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hipert.2020.02.005_bib0175","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/00004872-200305000-00011","article-title":"SCOPE Study Group The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial","volume":"21","author":"Lithel","year":"2003","journal-title":"J Hypertens"},{"key":"10.1016\/j.hipert.2020.02.005_bib0180","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1001\/archinternmed.2009.60","article-title":"ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses","volume":"169","author":"Wright","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.hipert.2020.02.005_bib0185","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/archinte.165.8.936","article-title":"Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs. a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"165","author":"Rahman","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.hipert.2020.02.005_bib0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-151-1-200907070-00122","article-title":"Effect of telmisartan on renal outcomes: a randomized trial","volume":"151","author":"Mann","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hipert.2020.02.005_bib0195","first-page":"253","article-title":"Heart outcomes prevention evaluation study investigators","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.hipert.2020.02.005_bib0200","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hipert.2020.02.005_bib0205","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hipert.2020.02.005_bib0210","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.hipert.2020.02.005_bib0215","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1093\/ndt\/gfp511","article-title":"The impact of stopping inhibitors of the renin\u2013angiotensin system in patients with advanced chronic kidney disease","volume":"25","author":"Ahmed","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.hipert.2020.02.005_bib0220","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.hipert.2020.02.005_bib0225","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/ndt\/gfv346","article-title":"Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor\/angiotensin receptor blocker withdrawal in advanced renaldisease: the STOP-ACEi trial","volume":"31","author":"Bhandari","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.hipert.2020.02.005_bib0230","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hipert.2020.02.005_bib0235","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","article-title":"Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)","volume":"362","author":"Fox","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.hipert.2020.02.005_bib0240","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.hipert.2020.02.005_bib0245","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1093\/ndt\/gfm396","article-title":"Elevated relative mortality risk with mild-to-moderate chronic kidney disease decreases with age","volume":"22","author":"Raymond","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.hipert.2020.02.005_bib0250","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1053\/j.ajkd.2018.06.010","article-title":"Use of renin\u2013angiotensin system blockade in advanced CKD: an NKF-KDOQI controversies report","volume":"72","author":"Weir","year":"2018","journal-title":"Am J Kidney Dis"}],"container-title":["Hipertensi\u00f3n y Riesgo Vascular"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1889183720300271?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1889183720300271?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T01:15:14Z","timestamp":1784596514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1889183720300271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S1889183720300271"],"URL":"https:\/\/doi.org\/10.1016\/j.hipert.2020.02.005","relation":{},"ISSN":["1889-1837"],"issn-type":[{"value":"1889-1837","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of renin\u2013angiotensin\u2013aldosterone system blockers on the progression of chronic kidney disease in hypertensive elderly patients without proteinuria: PROERCAN study. Rationale and design","name":"articletitle","label":"Article Title"},{"value":"Hipertensi\u00f3n y Riesgo Vascular","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hipert.2020.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 SEH-LELHA. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}